- Home
- FWONK vs DGX Comparison
FWONK vs DGX Comparison
Compare FWONK & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FWONK
- DGX
- Stock Information
- Founded
- FWONK 1950
- DGX 1967
- Country
- FWONK United States
- DGX United States
- Employees
- FWONK N/A
- DGX N/A
- Industry
- FWONK Broadcasting
- DGX Medical Specialities
- Sector
- FWONK Industrials
- DGX Health Care
- Exchange
- FWONK Nasdaq
- DGX Nasdaq
- Market Cap
- FWONK 24.9B
- DGX 20.1B
- IPO Year
- FWONK N/A
- DGX 1996
- Fundamental
- Price
- FWONK $99.71
- DGX $181.64
- Analyst Decision
- FWONK Buy
- DGX Buy
- Analyst Count
- FWONK 9
- DGX 15
- Target Price
- FWONK $109.67
- DGX $185.40
- AVG Volume (30 Days)
- FWONK 1.1M
- DGX 780.2K
- Earning Date
- FWONK 08-07-2025
- DGX 10-21-2025
- Dividend Yield
- FWONK N/A
- DGX 1.76%
- EPS Growth
- FWONK N/A
- DGX 12.66
- EPS
- FWONK 1.07
- DGX 8.35
- Revenue
- FWONK $3,866,000,000.00
- DGX $10,522,000,000.00
- Revenue This Year
- FWONK $20.50
- DGX $11.12
- Revenue Next Year
- FWONK $11.45
- DGX $3.41
- P/E Ratio
- FWONK $93.82
- DGX $21.76
- Revenue Growth
- FWONK 4.71
- DGX 12.58
- 52 Week Low
- FWONK $74.34
- DGX $146.17
- 52 Week High
- FWONK $106.26
- DGX $185.62
- Technical
- Relative Strength Index (RSI)
- FWONK 48.70
- DGX 59.34
- Support Level
- FWONK $98.50
- DGX $178.13
- Resistance Level
- FWONK $103.08
- DGX $180.89
- Average True Range (ATR)
- FWONK 1.92
- DGX 2.64
- MACD
- FWONK 0.09
- DGX -0.06
- Stochastic Oscillator
- FWONK 61.68
- DGX 60.44
About FWONK Liberty Media Corporation Series C Liberty Formula One
Liberty Media Corp along with its subsidiaries is engaged in the media and entertainment industries in North America and the United Kingdom. The company owns interests in a high-quality portfolio of assets across the media, entertainment and sports industries. The company derives its maximum revenue from United Kingdom.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.